Table 2. Six mRNAs significantly related to the overall survival of patients in the training set (n = 259).
| Gene symbol | Location | Length | P valuea | HRa (95% CI) | Coefficientb | Differential expressionc |
|---|---|---|---|---|---|---|
| FRMD5|84978 | 15q15.3 | 2560 | 3.11E-04 | 1.228 (1.10-1.37) | 0.072 | 0.0088 |
| PCMT1|5110 | 6q25.1 | 1888 | 6.92E-05 | 2.308 (1.53-3.49) | 0.512 | 0.0099 |
| PDGFA|5154 | 7p22 | 2804 | 1.80E-04 | 1.512 (1.22-1.88) | 0.201 | 0.001 |
| TMC8|147138 | 17q25.3 | 4417 | 5.77E-04 | 0.738 (0.62-0.88) | -0.158 | 0.0064 |
| YIPF4|84272 | 2p22.3 | 1963 | 4.66E-04 | 2.371 (1.46-3.84) | 0.615 | 0.019 |
| ZNF324B|388569 | 19q13.43 | 3812 | 6.63E-04 | 0.548 (0.39-0.77) | -0.145 | 0.021 |
a. The log-rank test in the univariate Cox regression analysis.
b. The coefficient value of the gene in the prognostic model of six mRNAs derived from the multivariate Cox regression analysis.
c. The value of differential expression significant level between long-term (>36 months) and short-term (<12 months) survival patients.